Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bexlosteride SCHEMBL29569846 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2 | |
| Bexlosteride SCHEMBL7194610 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2 | |
| Bexlosteride SCHEMBL13735634 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2 | |
| Bexlosteride SCHEMBL7798944 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2 | |
| Bexlosteride SCHEMBL225678 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2 | |
| SCHEMBL7798977 | 0.89 | SRD5A1 (0.80) | SRD5A1SRD5A2 | |
| SCHEMBL7798978 | 0.89 | SRD5A1 (0.80) | SRD5A1SRD5A2 | |
| SCHEMBL7798956 | 0.84 | SRD5A1 (1.00) | SRD5A1SRD5A2 | |
| SCHEMBL7796416 | 0.84 | SRD5A1 (1.00) | SRD5A1SRD5A2 | |
| SCHEMBL7796411 | 0.84 | SRD5A1 (1.00) | SRD5A1SRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 893 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4608405-A1 | COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL | Veradermics, Incorporated (US) | 2025-09-03 | — | — | EP | claimed |
| US-20250100986-A1 | BISPHENOL DERIVATIVES AND THEIR USE AS ANDROGEN RECEPTOR ACTIVITY MODULATORS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2025-03-27 | — | — | US | claimed |
| US-20250032470-A1 | Electrophilic Androgen Receptor (AR) Antagonists for AR Downregulation and Ferroptosis Induction in Cancer Cells | WAYNE STATE UNIVERSITY (US) | 2025-01-30 | — | — | US | claimed |
| US-12168803-B2 | Compositions and methods for screening and diagnosis of prostate cancer | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-12-17 | — | — | US | claimed |
| US-20240391883-A1 | HETEROCYCLIC COMPOUNDS FOR CANCER IMAGING AND TREATMENT AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2024-11-28 | — | — | US | claimed |
| EP-4446301-A2 | HETEROCYCLIC COMPOUNDS FOR CANCER IMAGING AND TREATMENT AND METHODS FOR THEIR USE | British Columbia Cancer Agency Branch (CA) | 2024-10-16 | — | — | EP | claimed |
| EP-3988541-B1 | HETEROCYCLIC COMPOUNDS FOR CANCER IMAGING AND TREATMENT AND METHODS FOR THEIR USE | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2024-06-26 | — | — | EP | claimed |
| WO-2024091572-A1 | COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL | VERADERMICS INCORPORATED (US) | 2024-05-02 | — | — | WO | claimed |
| EP-3442942-B1 | BISPHENOL DERIVATIVES AND THEIR USE AS ANDROGEN RECEPTOR ACTIVITY MODULATORS | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2023-11-15 | — | — | EP | claimed |
| US-11739069-B2 | Modulators of resistant androgen receptor | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2023-08-29 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| EP-0591583-B1 | Benzo (f) quinolinones as 5-alpha-reductase inhibitors | LILLY CO ELI (US) | 2001-12-19 | — | — | EP | claimed |
| EP-0532190-B1 | Benzo(f)quinolinones as 5-alpha-reductase inhibitors | LILLY CO ELI (US) | 2000-12-27 | — | — | EP | claimed |
| US-5541190-A | TREATING BENIGN PROSTATIC HYPERPLASIA, MALE PATTERN BALDNESS, PROSTATIC CANCER, ANDROGENIC ALOPECIA | ELI LILLY AND COMPANY (US) | 1996-07-30 | — | — | US | claimed |
| EP-0591583-A1 | Benzo (f) quinolinones as 5-alpha-reductase inhibitors | ELI LILLY AND COMPANY (US) | 1994-04-13 | — | — | EP | claimed |
| EP-0532190-A2 | Benzo f quinolinones as 5-alpha-reductase inhibitors | ELI LILLY AND COMPANY (US) | 1993-03-17 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250100986-A1 | BISPHENOL DERIVATIVES AND THEIR USE AS ANDROGEN RECEPTOR ACTIVITY MODULATORS | AR, SHBG, NR5A1 | SRD5A1 17/4885SRD5A2 29/4885 |
| US-20240391883-A1 | HETEROCYCLIC COMPOUNDS FOR CANCER IMAGING AND TREATMENT AND METHODS FOR THEIR USE | AR, KLK3, GNRHR | SRD5A1 10/4885SRD5A2 42/4885 |
| US-11739069-B2 | Modulators of resistant androgen receptor | AR, NR5A1, ESRRA | SRD5A1 29/4885SRD5A2 27/4885 |
| US-20250032470-A1 | Electrophilic Androgen Receptor (AR) Antagonists for AR Downregulation and Ferroptosis Induction in Cancer Cells | AR, GSR, GPX1 | SRD5A1 340/4885SRD5A2 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.